Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on September 12, 2025. The report discloses a Regulation FD event regarding the presentation of the Company's product candidate, CDI-988, at the 9th International Calicivirus Conference held in Banff, Alberta, from September 7–11, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary update is the dissemination of information regarding the CDI-988 product candidate by President and co-CEO Dr. Sam Lee, PhD.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) containing details of the conference discussion but does not include specific forward-looking guidance, management commentary, or risk factors within the body of this 8-K. The document explicitly states that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated September 12, 2025) for specific details on the CDI-988 presentation.
- Verify the clinical development status of CDI-988 through the Company's latest periodic reports (10-K or 10-Q).
- Confirm the Company's cash position and runway in the most recent audited financial statements, as this 8-K contains no liquidity data.